Best confirmed hematologic response to dasatinib
| . | No. (%) of patients . | |
|---|---|---|
| 6 months' follow-up | 8 months' follow-up | |
| Overall hematologic response | 17 (47) | 18 (50) |
| Major hematologic response | 15 (42) | 15 (42) |
| CHR | 11 (31) | 12 (33) |
| NEL | 4 (11) | 3 (8) |
| Minor hematologic response | 2 (6) | 3 (8) |
| No response | 19 (53) | 18 (50) |
| . | No. (%) of patients . | |
|---|---|---|
| 6 months' follow-up | 8 months' follow-up | |
| Overall hematologic response | 17 (47) | 18 (50) |
| Major hematologic response | 15 (42) | 15 (42) |
| CHR | 11 (31) | 12 (33) |
| NEL | 4 (11) | 3 (8) |
| Minor hematologic response | 2 (6) | 3 (8) |
| No response | 19 (53) | 18 (50) |
Number of patients in each column was 36.